PortfoliosLab logoPortfoliosLab logo
IDNA vs. SURI
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

IDNA vs. SURI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and Simplify Propel Opportunities ETF (SURI). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, IDNA achieves a 9.51% return, which is significantly higher than SURI's 7.33% return.


IDNA

1D
-2.18%
1M
-2.18%
YTD
9.51%
6M
10.53%
1Y
41.74%
3Y*
6.48%
5Y*
-8.26%
10Y*

SURI

1D
-1.45%
1M
0.71%
YTD
7.33%
6M
5.21%
1Y
37.33%
3Y*
7.35%
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

IDNA vs. SURI - Yearly Performance Comparison


Correlation

The correlation between IDNA and SURI is 0.51, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.51

Correlation (3Y)
Calculated over the trailing 3-year period

0.62

Correlation (All Time)
Calculated using the full available price history since Feb 9, 2023

0.63

The correlation between IDNA and SURI shifts across timeframes, from 0.51 (1 year) to 0.62 (all time), reflecting how their relationship changes across market environments.

IDNA vs. SURI - Sectors Allocation Comparison


Sectors
IDNA
SURI

Healthcare

97.8%
56.4%

Industrials

0.4%

-

Basic Materials

-

-

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

43.6%

Financial Services

-

-

Real Estate

-

-

Technology

-

-

Utilities

-

-

Healthcare

IDNA
97.8%
SURI
56.4%

Industrials

IDNA
0.4%
SURI

-

Basic Materials

IDNA

-

SURI

-

Communication Services

IDNA

-

SURI

-

Consumer Cyclical

IDNA

-

SURI

-

Consumer Defensive

IDNA

-

SURI

-

Energy

IDNA

-

SURI
43.6%

Financial Services

IDNA

-

SURI

-

Real Estate

IDNA

-

SURI

-

Technology

IDNA

-

SURI

-

Utilities

IDNA

-

SURI

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

IDNA vs. SURI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IDNA
IDNA Risk / Return Rank: 5757
Overall Rank
IDNA Sharpe Ratio Rank: 4949
Sharpe Ratio Rank
IDNA Sortino Ratio Rank: 5050
Sortino Ratio Rank
IDNA Omega Ratio Rank: 4343
Omega Ratio Rank
IDNA Calmar Ratio Rank: 7979
Calmar Ratio Rank
IDNA Martin Ratio Rank: 6464
Martin Ratio Rank

SURI
SURI Risk / Return Rank: 5151
Overall Rank
SURI Sharpe Ratio Rank: 4646
Sharpe Ratio Rank
SURI Sortino Ratio Rank: 4747
Sortino Ratio Rank
SURI Omega Ratio Rank: 4444
Omega Ratio Rank
SURI Calmar Ratio Rank: 6666
Calmar Ratio Rank
SURI Martin Ratio Rank: 5454
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IDNA vs. SURI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and Simplify Propel Opportunities ETF (SURI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


IDNASURIDifference

Sharpe ratio

Return per unit of total volatility

1.71

1.65

+0.06

Sortino ratio

Return per unit of downside risk

2.48

2.34

+0.14

Omega ratio

Gain probability vs. loss probability

1.28

1.29

-0.01

Calmar ratio

Return relative to maximum drawdown

4.09

3.33

+0.77

Martin ratio

Return relative to average drawdown

11.79

9.47

+2.31

IDNA vs. SURI - Sharpe Ratio Comparison

The current IDNA Sharpe Ratio is 1.71, which is comparable to the SURI Sharpe Ratio of 1.65. The chart below compares the historical Sharpe Ratios of IDNA and SURI, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


IDNASURIDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.71

1.65

+0.06

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.29

Sharpe Ratio (All Time)

Calculated using the full available price history

0.10

0.16

-0.07

Drawdowns

IDNA vs. SURI - Drawdown Comparison

The maximum IDNA drawdown since its inception was -68.26%, which is greater than SURI's maximum drawdown of -47.76%. Use the drawdown chart below to compare losses from any high point for IDNA and SURI.


Loading charts...

Drawdown Indicators


IDNASURIDifference

Max Drawdown

Largest peak-to-trough decline

-68.26%

-47.76%

-20.50%

Max Drawdown (1Y)

Largest decline over 1 year

-10.66%

-11.78%

+1.12%

Max Drawdown (3Y)

Largest decline over 3 years

-29.73%

-47.76%

+18.03%

Max Drawdown (5Y)

Largest decline over 5 years

-68.26%

Current Drawdown

Current decline from peak

-46.01%

-16.51%

-29.50%

Average Drawdown

Average peak-to-trough decline

-36.24%

-17.37%

-18.87%

Ulcer Index

Depth and duration of drawdowns from previous peaks

3.70%

4.13%

-0.43%

Volatility

IDNA vs. SURI - Volatility Comparison

iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) has a higher volatility of 7.24% compared to Simplify Propel Opportunities ETF (SURI) at 6.32%. This indicates that IDNA's price experiences larger fluctuations and is considered to be riskier than SURI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


IDNASURIDifference

Volatility (1M)

Calculated over the trailing 1-month period

7.24%

6.32%

+0.92%

Volatility (6M)

Calculated over the trailing 6-month period

18.21%

14.26%

+3.95%

Volatility (1Y)

Calculated over the trailing 1-year period

24.51%

22.78%

+1.73%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

28.42%

28.28%

+0.14%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

29.53%

28.28%

+1.25%

IDNA vs. SURI - Expense Ratio Comparison

IDNA has a 0.47% expense ratio, which is lower than SURI's 2.51% expense ratio.


Dividends

IDNA vs. SURI - Dividend Comparison

IDNA's dividend yield for the trailing twelve months is around 1.08%, less than SURI's 15.86% yield.


PositionTTM2025202420232022202120202019
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund
1.08%1.18%0.98%1.04%0.54%0.70%0.26%0.80%
SURI
Simplify Propel Opportunities ETF
15.86%16.31%21.41%14.71%0.00%0.00%0.00%0.00%

Frequently Asked Questions


IDNA and SURI have a correlation of 0.51, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

IDNA has higher volatility (7.24%) compared to SURI (6.32%). In terms of maximum drawdown, IDNA dropped -68.26% vs SURI's -47.76%.

On 3-year performance, SURI leads with 7.35% vs 6.48% for IDNA. On fees, IDNA is cheaper at 0.47% per year. On volatility, SURI has been the lower-risk option at 6.32%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 3-year period, SURI has performed better with a 7.35% return vs 6.48%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

IDNA is cheaper with a 0.47% expense ratio, compared with 2.51% for SURI.

SURI has the higher dividend yield at 15.86%, compared with 1.08% for IDNA.

They also come from different issuers: iShares and Simplify. Their fees differ too: 0.47% for IDNA and 2.51% for SURI.

IDNA currently has the higher Sharpe Ratio (1.71 vs 1.65), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for IDNA and SURI

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer